KEYNOTE-826
Does pembrolizumab added to platinum chemotherapy with or without bevacizumab improve outcomes in advanced cervical cancer?
Trial design and population
Registry: undefined.
Key results
PD-L1 CPS ≥1: median OS 28.6 vs 16.5 months (HR 0.60, 95% CI 0.49–0.74). All-comer median OS 26.4 vs 16.8 months (HR 0.63, 95% CI 0.52–0.77).
Outcome visualization
Median OS, CPS ≥1 · final OS analysis · 28.6
Bars scale to the larger reported value. Median survival values are time-to-event summaries, not fixed-time absolute event risks.
Absolute Effect
Endpoint/time horizon: Median OS, CPS ≥1 · final OS analysis · 28.6.
NNT: Not calculated from median survival or hazard ratios; calculate only from defensible fixed-time absolute risks.
NNH: Not calculated unless a fixed-time excess-harm risk difference is available. Check CPS, histology, autoimmune history and bevacizumab suitability. Median survival differences are not fixed-time risks and cannot be converted into NNT.
Safety, burden and QoL
Check CPS, histology, autoimmune history and bevacizumab suitability. Median survival differences are not fixed-time risks and cannot be converted into NNT.
QoL and discontinuation percentages are not asserted where not verified from the full primary report; complete source-table audit remains a QC item.
Subgroups, maturity and limitations
https://pubmed.ncbi.nlm.nih.gov/35139273/
Distinguish prespecified from exploratory subgroups, immature from mature endpoints, and superiority from non-inferiority. Historical comparators may not represent all current treatment sequences.
Current-practice context · 21 October 2026
Verify current guidelines, regulatory status, biomarker requirements, prior treatment, comorbidities and patient goals before applying these historical trial results. Clinical freshness and full QoL/toxicity source review remain open where noted.